In bone loss induced by hyperhomocysteinemia (HHcy), NaSH epigenetically mitigates bone loss through osteoprotegerin (OPG)/receptor activator of nuclear factor kappa-B ligand (RANKL) regulation (Behera et al., 2018a). This evidence concerns the gene TNFSF11 and hyperhomocysteinemia.